Skolkovo?s first Belarusian resident develops new antifungal drugs

Skolkovo?s first Belarusian resident develops new antifungal drugsTarget Medicals, a Minsk biotech company and Skolkovo?s first Belarusian resident, engages in Russia in the development of new synthetic antimycotic drugs.

Target Medicals, a Minsk biotech company and Skolkovo?s first Belarusian resident, engages in Russia in the development of new synthetic antimycotic (antifungal) drugs, using the insilico and invitro screening techniques, Belarusian website It.tut.by reports. Target Medicals was set up last October by researchers from the Institute of Bioorganic Chemistry (part of the Belarusian National Academy of Sciences) and by Alexei Klyuchenovich, a former physician of the Minsk Regional Clinical Hospital and now a local businessman. Mr. Klyuchenovich is currently the CEO of the Minsk start-up. The company and the Institute of Bioorganic Chemistry have jointly developed innovation drug candidates and purified recombinant (chimeric) proteins. In late 2012, the start-up joined Russia?s Skolkovo, the state-sponsored innovation hub under construction outside Moscow. Target Medicals? antifungal project is still on the so-called ?grantless? list of Skolkovo?s Biomed cluster participants?a status that a reported 176 out of the cluster?s 209 residents now have. But the Belarusian start-up hopes that investors will be interested...